Edema in DME and AMD can be significantly reduced with anti-VEGFA therapies [123]; however, recent studies in the mouse suggest that global VEGFA blockade in retinal diseases might have detrimental side effects in the long-term. The gene discussed is VEGFA; the disease is age-related macular degeneration.